DUPIXENT is a biologic with a
novel approach to treating
uncontrolled
moderate-to-severe atopic
dermatitis in patients aged
12 years and older1
Consider referring to a
DERMATOLOGIST or ALLERGIST
DERMATOLOGIST or ALLERGIST
today to see what’s
possible with DUPIXENT
possible with DUPIXENT
When topical Rx therapies aren’t enough, DUPIXENT may be appropriate
Patients may be appropriate for DUPIXENT if they:
- Have tried a variety of topical prescription therapies and are still uncontrolled
- Suffer from inadequate control of pruritus
- Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet
- Have moderate‑to‑severe erythema and moderate-to-severe papulation/infiltration (IGA 3=moderate or 4=severe)
Consider referring your patients to a specialist today
Partner with an eczema specialist to help your patients. Use the HealthgradesTM tool to easily find nearby eczema specialists with experience in treating adolescents and adults with uncontrolled moderate-to-severe atopic dermatitis.
Other treatments don’t specifically target key
sources of underlying inflammation2
Atopic dermatitis is a chronic, recurring, and systemic disease, leaving patients trapped
in an endless cycle of flares driven in part by persistent underlying inflammation.2,3
DUPIXENT targets a key source of the underlying inflammation of atopic dermatitis1
DUPIXENT systematically addresses inflammation in a more targeted manner than topical Rx therapies and systemic steroids1-4
DUPIXENT is Revolutionizing
Atopic Dermatitis
Atopic Dermatitis
DUPIXENT has proven efficacy and demonstrated long-term safety in moderate‑to‑severe atopic dermatitis uncontrolled with topical Rx therapy1
Itch relief1
Clear or almost-clear skin and improvement
in lesion extent and severity1
Demonstrated safety profile1
DUPIXENT is not an
immunosuppressant
or a
steroid1
There is no requirement for
initial lab testing or
ongoing
lab monitoring according to
the
Prescribing Information1
The most common adverse reactions (incidence ≥1% at Week 16) were injection site reactions, conjuctivitis, blepharitis, oral herpes, keratitis, eye pruritis, other herpes simplex virus infection, and dry eye1
a IQVIA National Prescription Audit (NPA) data as of September 2019. b New patients across all indications.
Trial Designs and Results
A total of 917 adult patients in Trials 1 and 2 (16-week trials), 251 adolescent patients in Trial 6 (16-week trial), and 421 adult patients in Trial 3 (52-week trial) with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT or placebo. For all patients in Trial 3, lesions were treated with concomitant TCS. All adults received 300 mg Q2W following a 600 mg loading dose. Adolescents ≥60 kg also received this dose, while adolescents ≤60 kg received 200 mg Q2W following a 400 mg loading dose. Eligible patients had an IGA score ≥3 (overall atopic dermatitis lesion severity scale of 0 to 4), an EASI score ≥16 on a scale of 0 to 72, and body surface area involvement of ≥10%. At baseline, 52% of adults and 46% of adolescents had an IGA score of 3 (moderate atopic dermatitis), 48% of adults and 54% of adolescents had an IGA of 4 (severe atopic dermatitis), mean EASI score was 33 for adults and 36 for adolescents, and weekly averaged Peak Pruritus NRS was 7 on a scale of 0 to 10 for adults and 8 for adolescents.1
The primary endpoint was the change from baseline in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and a ≥2-point improvement at Week 16 (38% and 36% of adults treated with DUPIXENT vs 10% and 9% with placebo in Trials 1 and 2, respectively, P≤0.001; 24% of adolescents treated with DUPIXENT vs 2% with placebo in Trial 6, P<0.0001; 39% of adults treated with DUPIXENT + TCS vs 12% with placebo + TCS in Trial 3, P<0.0001). Other endpoints included change from baseline in the proportion of subjects with EASI-75 at Week 16 (improvement of ≥75%; 51% and 44% of adults treated with DUPIXENT vs 15% and 12% with placebo in Trials 1 and 2, respectively, P<0.001; 42% of adolescents treated with DUPIXENT vs 8% with placebo in Trial 6, P<0.0001; 69% of adults treated with DUPIXENT + TCS vs 23% with placebo + TCS in Trial 3, P<0.0001) and reduction in itch as defined by ≥4-point improvement in the Peak Pruritus NRS at Week 16 (41% and 36% of adults treated with DUPIXENT vs 12% and 10% with placebo in Trials 1 and 2, respectively, P<0.001; 37% of adolescents treated with DUPIXENT vs 5% with placebo in Trial 6, P<0.0001; 59% of adults treated with DUPIXENT + TCS vs 20% with placebo + TCS in Trial 3, P<0.0001).1,7-9
EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.